Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare aggressive rhabdomyosarcoma occurring in children. The neoplasm is characterized by the presence of bizarre round, spindle, and polygonal cells.
Biomarker and diagnostic research for childhood pleomorphic rhabdomyosarcoma has been reported in the published literature.
5 clinical trials registered, 3 recruiting. Interventions under study include procedural interventions, other interventions, biologic therapy, and drug therapy. Pipeline includes 3 PHASE2, 1 PHASE1, 1 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07169344](https://clinicaltrials.gov/study/NCT07169344) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:57 PM UTC
Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma |
PHASE2 |
Oslo University Hospital |
RECRUITING |
[NCT06526897](https://clinicaltrials.gov/study/NCT06526897) | Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma | NA | ECOG-ACRIN Cancer Research Group | NOT_YET_RECRUITING |
[NCT04420975](https://clinicaltrials.gov/study/NCT04420975) | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | PHASE1 | Jonsson Comprehensive Cancer Center | ACTIVE_NOT_RECRUITING |
[NCT06277154](https://clinicaltrials.gov/study/NCT06277154) | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | PHASE2 | HRYZ Biotech Co. | RECRUITING |
[NCT07173972](https://clinicaltrials.gov/study/NCT07173972) | Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. | PHASE2 | Oslo University Hospital | RECRUITING |
55 publications have been identified in PubMed for childhood pleomorphic rhabdomyosarcoma. Research spans Case Report / Case Series (60%), Review / Meta-Analysis (13%), and Basic Science / Preclinical (9%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 33 | 60% |
Research summaries | 7 | 13% |
Laboratory research | 5 | 9% |
Clinical study results | 4 | 7% |
Disease patterns and progression | 4 | 7% |
Testing and diagnosis research | 1 | 2% |
New treatment approaches | 1 | 2% |
Evele G (2026). [PMID: 42125161](https://pubmed.ncbi.nlm.nih.gov/42125161/). *Clin Case Rep*. [Case Report / Case Series]
Ma JQ (2026). [PMID: 41607761](https://pubmed.ncbi.nlm.nih.gov/41607761/). *World J Gastrointest Oncol*. [Case Report / Case Series]
Giani C (2026). [PMID: 41564817](https://pubmed.ncbi.nlm.nih.gov/41564817/). *ESMO Open*. [Case Report / Case Series]
Honaker EC (2026). [PMID: 41870331](https://pubmed.ncbi.nlm.nih.gov/41870331/). *Int J Surg Pathol*. [Review / Meta-Analysis]
Ulici V (2026). [PMID: 41780801](https://pubmed.ncbi.nlm.nih.gov/41780801/). *Mod Pathol*. [Basic Science / Preclinical]
Meet S (2026). [PMID: 41735791](https://pubmed.ncbi.nlm.nih.gov/41735791/). *Diagn Cytopathol*. [Case Report / Case Series]
Margotte L (2026). [PMID: 41666515](https://pubmed.ncbi.nlm.nih.gov/41666515/). *Eur J Surg Oncol*. [Epidemiology / Natural History]
Mijares K (2026). [PMID: 41984283](https://pubmed.ncbi.nlm.nih.gov/41984283/). *Head Neck Pathol*. [Gene Therapy / Novel Therapeutics]
Yeung MCF (2026). [PMID: 42192570](https://pubmed.ncbi.nlm.nih.gov/42192570/). *Genes Chromosomes Cancer*. [Basic Science / Preclinical]
Baldi GG (2026). [PMID: 41819027](https://pubmed.ncbi.nlm.nih.gov/41819027/). *Eur J Cancer*. [Clinical Trial Publication]
AI-curated news mentioning childhood pleomorphic rhabdomyosarcoma
Updated Jun 12, 2026
A study of 39 mismatch repair-deficient sarcomas reveals recurrent histologic patterns, advocating for universal screening of pleomorphic rhabdomyosarcoma, uterine leiomyosarcoma, and undifferentiated and unclassified sarcomas. This research could influence future diagnostic and treatment strategies.
A retrospective study from the PUSH consortium evaluates outcomes in patients with advanced pleomorphic rhabdomyosarcoma treated with systemic agents. The findings contribute to understanding treatment efficacy in this ultra-rare sarcoma subtype.